Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-05-19

Clinical Trial Update: The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain [Phase 4]

View source ↗

Summary

This Phase 4 study evaluates the effectiveness of Almotriptan Malate (AXERT) 12.5 mg when taken at the onset of migraine pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Axert (Almotriptan)

Snippet

Sponsor: Ortho-McNeil Neurologics, Inc. | Conditions: Migraine | Phase 4 | Status: COMPLETED